A spirited pro/con debate at ERA 2025 explores whether population-level albuminuria screening could improve early CKD detection, with feasibility, cost-effectiveness, and equity all weighed.

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

The collaboration brings together the medical expertise of Thammasat University Hospital and the global healthcare innovation of Novo Nordisk, with a shared vision of delivering more than just disease ...